期刊文献+

多柔比星对大鼠心肝肾及免疫器官的长期毒性作用

Long-term toxic effects of doxorubicin on heart,liver,kidney and immune organs in rats
下载PDF
导出
摘要 目的探讨多柔比星(DOX)对大鼠心肝肾及免疫器官的长期毒性作用。方法将48只健康SD大鼠随机分为DOX 7.0、14.0、28.0 mg/m^2组及溶剂对照组,分别给予0.23、0.47、0.93 mg/L DOX 30 mL/m^2及等体积的5%葡萄糖注射液经尾静脉推注,每3周给药1次,共给药4次。给药结束,用20%乌来糖腹腔注射麻醉,经腹主动脉取血,剖取心脏、肝脏、肾脏、胸腺、脾和肠系膜淋巴结以备用。用罗氏全自动生化分析仪检测血液生化指标,用流式细胞术检测外周血淋巴细胞亚群,计算脏器系数,观察脏器组织病理变化。结果与溶剂对照组比较,DOX 7.0 mg/m^2组血液生化指标变化不明显(P均>0.05),DOX 14.0、28.0 mg/m^2组天门冬氨酸氨基转移酶、血尿素氮、肌酐高(P均<0.05),DOX 28.0 mg/m^2组丙氨酸氨基转移酶高(P<0.05);各组血清肌酸激酶水平比较差异无统计学意义(P均>0.05)。DOX 14.0、28.0 mg/m^2组CD3+、CD4+、CD8+T细胞亚群及CD45RA+B细胞亚群计数、CD4+/CD8+与溶剂对照组比较差异有统计学意义(P均<0.05)。DOX 14.0 mg/m^2组肝脏、肾脏、胸腺脏器系数及DOX 28.0 mg/m^2组的各器官脏器系数与溶剂对照组比较差异有统计学意义(P均<0.05)。DOX 7.0、14.0、28.0 mg/m^2组见心脏心肌细胞空泡变性、坏死;DOX 28.0 mg/m^2组见肝细胞空泡变性;DOX 14.0、28.0 mg/m^2组见肾病综合征表现;DOX 14.0、28.0 mg/m^2组胸腺、脾脏、淋巴结发生萎缩。结论DOX对SD大鼠的心脏、肝脏、肾脏和免疫器官有明显的长期毒性作用,表现为心肌细胞的变性坏死、肝细胞变性、肾病综合征、免疫器官萎缩。 Objective To investigate the long-term toxicity of doxorubicin(DOX)on heart,liver,kidney,and immune organs in rats.Methods Forty-eight healthy SD rats were randomly divided into the DOX 7.0,14.0,28.0 mg/m^2 groups and solvent control group,which were injected intravenously via tail vein with 0.23,0.47,and 0.93 mg/L DOX 30 mL/m^2,and an equal volume of 5%glucose.The drug was administered once every 3 weeks,for 4 times.At the end of the administration,they were anesthetized intraabdominal with 20%urai sugar.Blood was taken through the abdominal aortic artery and the heart,liver,kidney,thymus,spleen and mesenteric lymph nodes were cut out for backup.The blood biochemical indexes of rats were detected by Roche automatic biochemical analyzer,the peripheral blood lymphocyte subsets of rats were detected by flow cytometry,the organ coefficient was calculated,and the pathological changes of rat organs were observed.Results Compared with the solvent control group,there was no significant change in blood biochemical indexes in the DOX 7.0 mg/m^2 group(P>0.05),AST,BUN,and CRE were higher in the DOX 14.0 and 28.0 mg/m^2 groups(all P<0.05),and ALT was higher in the DOX 28.0 mg/m^2 group(P<0.05);there was no significant difference in serum CK level between groups(P>0.05).Significant differences were found in the number of CD3+,CD4+,CD8+T cell subpopulation,CD45RA+B cell subpopulation and and CD4/CD8 between the solvent control group and the DOX 14.0 and 28.0 mg/m^2 groups(all P<0.05).Compared with the solvent control group,the organ coefficients of heart,liver and kidney were higher in the DOX 7.0,14.0 and 28.0 mg/m^2 groups,the organ coefficients of thymic gland and spleen were lower.The organ coefficients of liver,kidney,thymus in DOX 14.0 mg/m^2 group and organ coefficient of each organ in DOX 28.0 mg/m^2 were significantly different from those in the control group(P<0.05).DOX 7.0,14.0,28.0 mg/m^2 group showed vacuole degeneration and necrosis of cardiac myocytes;DOX 14.0,28.0 mg/m^2 groups showed nephrotic syndrome;atrophy of the thymus,spleen and lymph nodes occurred in the DOX 14.0 and 28.0 mg/m^2 groups.Conclusion DOX has obvious toxic effects on heart,liver,kidney and immune organs of SD rats,such as degeneration and necrosis of cardiac myocytes,degeneration of liver cells,nephrotic syndrome,and atrophy of immune organs,and the effect is dose-dependent.
作者 于靖 裴天仙 YU Jing;PEI Tianxian(Tianjin Chest Hospital,Tianjin 300051,China)
出处 《山东医药》 CAS 2020年第1期40-43,共4页 Shandong Medical Journal
关键词 多柔比星 药物毒性 大鼠 doxorubicin drug toxicity rats
  • 相关文献

参考文献4

二级参考文献32

  • 1钟灼,张思群,肖桂元,罗蔚桓,全佩城,冯愉态.微量肝素治疗播散性血管内凝血的临床研究[J].临床血液学杂志,1994,7(3):106-110. 被引量:9
  • 2郭长升,唐家宏,宋宗昌,朱璐.VAD方案联合全反式维甲酸治疗难治性多发性骨髓瘤12例[J].第三军医大学学报,2006,28(24). 被引量:3
  • 3邓春晓,梁桂珍,邓才英.单纯亚砷酸联合维甲酸治疗急性早幼粒细胞白血病不良反应6年观察及对策[J].齐齐哈尔医学院学报,2007,28(12):1411-1412. 被引量:7
  • 4Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with a- cute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups [ J ]. Blood, 2000,96 ( 4 ) : 1247 - 1253.
  • 5张之楠,沈悌.血液病怎的及治疗标准[M].2版.北京出版社,1998:74.
  • 6Mistry AR, Pedersen EW, Solomon E, et al. The molecular pathogen- esis of acute promyelocytic leukemia: implications for the clinical management of the disease [ J ]. Blood Rev,2003,17 ( 2 ) :71 - 97.
  • 7Tallman MS, Anderson JW, Schiffer CA, et al. All-transretinoic acid in acute promyelocytic leukemia [ J]. N Engl J Med, 1997,337 (15) :1021 -1028.
  • 8Wang ZY, Chen Z. Acute promyelocytic leukemia:from highly fatal to highly curable [ J ]. Blood,2008,111 (5) :2505 - 2515.
  • 9Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation thera- py of acute promyelocytic leukemia with tretinoin ( all-transretinoic acid) [J]. N Engl J Med,1991,324 (20) :1385 - 1393.
  • 10Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide ( As203 ) in the treatment of acute promyelocytie leukemia (APL) :I, As203 ex- erts dose-dependent daul effects on APL cells [ J]. Blood, 1997,89 (9) :3345 -3353.

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部